Search
Uniqure NV
QUREAdd to Watchlist
45.170USD
-0.890-1.93%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
2.85BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-30The current earnings forecast score of Uniqure NV is 8.27, ranking 143 out of 387 in the Biotechnology & Medical Research industry. The average price target is 53.00, with a high of 95.00 and a low of 30.00.
Analyst Rating
Based on
15
analysts
Buy
Current Rating
64.833
Target Price
+40.76%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Uniqure NV
QURE
15
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Uniqure NV's expected revenue for the next quarter?
Uniqure NV's expected revenue is 5.47M.
What is Uniqure NV's price target?
Analysts forecast that Uniqure NV's price target is USD 53.00, with the highest forecast at USD 95.00 and the lowest forecast at USD 30.00.
How have Uniqure NVQURE's recent earnings per share performed?
The market expectation was USD -0.85, while Uniqure NVQURE's earnings per share (EPS) for the previous quarter was USD -0.59. EPS for the next quarter is expected at USD -0.84.
What is the analyst rating for Uniqure NV?
Based on the ratings of Uniqure NV's stock from 15 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.